170411 ⎘
Assays involving biological materials from specific organisms or of a specific nature from animals; from humans; Assays involving growth factors Angiogenesic factors; Angiogenin
SYSTEM FOR DETECTING INFECTION IN SYNOVIAL FLUID
#2BLADDER CANCER BIOMARKERS AND METHODS OF USE
#3ANTIBODY OR ANTIGEN-BINDING FRAGMENT CAPABLE OF IDENTIFYING ANG-2, AND BISPECIFIC ANTIBODY FOR SIMULTANEOUSLY IDENTIFYING VEGF AND ANG-2
#4BLOOD BIOMARKERS IN LONG-COVID-19
#5CMYBPC MARKER COMBINATIONS FOR EARLY DISCRIMINATION OF TYPE 2 VERSUS TYPE 1 ACUTE MYOCARDIAL INFARCTION
#6MEANS AND METHODS APPLYING sFlt-1/PIGF OR ENDOGLIN/PIGF RATIO TO RULE OUT ONSET OF PREECLAMPSIA WITHIN A CERTAIN TIME PERIOD
#7RATIOS OF sFlt-1 TO P1GF OR ENDOGLIN TO P1GF AS BIOMARKERS FOR PREECLAMPSIA RELATED ADVERSE OUTCOMES AFTER BIRTH
#8ANALYSIS OF VITREOUS SAMPLES TO GUIDE TREATMENT
#9Method for Predicting Effectiveness of Angiogenesis Inhibitor
#10SYSTEM FOR DETECTING INFECTION IN SYNOVIAL FLUID
#11BIOMARKERS AND USES THEREOF FOR SELECTING IMMUNOTHERAPY INTERVENTION
#12PREECLAMPSIA BIOMARKERS AND RELATED SYSTEMS AND METHODS
#13Circulating tumor markers for meningiomas
#14Preeclampsia biomarkers and related systems and methods
#15Aluminum metasurfaces for highly sensitive and enhanced detection of analytes for smartphone diagnostics and methods for making and using the same
#16CIRCULATING SPON-1 (SPONDIN-1) IN THE ASSESSMENT OF ATRIAL FIBRILLATION
#17METHOD FOR MONITORING DEVELOPMENT OF THE CENTRAL NERVOUS SYSTEM
#18Ratios of sFlt-1 to P1GF or endoglin to P1GF as biomarkers for preeclampsia related adverse outcomes after birth
#19BIOMARKERS FOR RISK PREDICTION OF MORTALITY
#20METHOD FOR EVALUATING AND METHOD FOR MONITORING THERAPEUTIC EFFECT IN CRITICAL LIMB ISCHEMIA PATIENT WHO HAS UNDERGONE ANGIOGENIC THERAPY, REAGENT FOR EVALUATING THERAPEUTIC EFFECT, AND DEVICE AND COMPUTER PROGRAM FOR EVALUATING THERAPEUTIC EFFECT
#21Circulating Angiopoietin-2 (Ang-2) and insulin-like growth factor-binding protein 7 (IGFBP7) for the prediction of stroke
#22PREECLAMPSIA BIOMARKERS AND RELATED SYSTEMS AND METHODS
#23Method for Predicting Effectiveness of Angiogenesis Inhibitor
#24Biomarkers and uses thereof for selecting immunotherapy intervention
#25METHOD FOR MONITORING FETUS/PRETERM INFANT DEVELOPMENT, AND FOR PROMOTING THE NORMAL DEVELOPMENT OF PRETERM INFANTS
#26System for detecting infection in synovial fluid
#27Detection of angiopoietin-2 and thrombospondin-2 in connection with diagnosing acute heart failure
#28Humanized or affinity-matured anti ang-2 antibody and uses thereof
#29ANGPTL4 AS A PROGNOSTIC MARKER FOR BLADDER CANCER
#30ANTI-ANGIOGENIC VEGF-AX ISOFORM
#31Angiopoietin-like 4 and a method of its use in wound healing
#32Method for the diagnosis of disorders caused by fetal alcohol syndrome
#33Cardiovascular risk event prediction and uses thereof
#34COMPOSITIONS AND METHODS FOR MODULATING PRO-INFLAMMATORY IMMUNE RESPONSE
#35Anti-ANG2 antibody
#36Methods and compositions in diagnosis of chronic fatigue syndrome/myalgic encephalomyelitis
#37Method for measurement of peptidic degradation products of a proteolytic cascade in blood samples
#38Method For Predicting Effectiveness Of Angiogenesis Inhibitor
#39Process and compositions for achieving mammalian energy balance
#40Biomarker and methods for early diagnosis of Alzheimer's disease
#41PREDICTION OF POSTPARTUM HELLP SYNDROME, POSTPARTUM ECLAMPSIA OR POSTPARTUM PREECLAMPSIA
#42Methods for Determining The Risk of Prenatal Complications
#43METHODS AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF DISEASES CHARACTERIZED BY VASCULAR LEAK, HYPOTENSION, OR A PROCOAGULANT STATE
#44Methods of treating mesothelioma by administration of compounds comprising FGFR1 ECD
#45Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
#46Vascular endothelial growth factor-binding aptamers
#47Angiopoietin-related protein 4 (cAngptl4) as a diagnostic biomarker for acute lung damage
#48Means and methods applying sFlt-1/PlGF or endoglin/PlGF ratio to rule out onset of preeclampsia within a certain time period
#49Humanized or affinity-matured anti Ang-2 antibody and uses thereof
#50VEGF-A121 ASSAY
#51VEGF-Aassay
#52Binding partners of the placental growth factor, especially antibodies directed against the placental growth factor, and production and use thereof
#53Antibody specifically binding to ANG2 and use thereof
#54Angiopoietin-like 4 and a method of its use in wound healing
#55Blood biomarkers for necrotizing enterocolitis
#56DIAGNOSTIC METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER
#57Method for measurement of peptidic degradation products of a proteolytic cascade in blood samples
#58Method of blocking vascular leakage using an anti-ANG2 antibody
#59Anti-Ang2 antibody
#60Ang-2 specific antibodies and uses thereof
#61Determination of sFlt-1:angiogenic factor complex
#62VEGF-specific capture agents, compositions, and methods of using and making
#63Induction of the mitochondrial permeability transition
#64Methods for determining the risk of prenatal complications
#65Use of nucleolin as a biomarker for lymphangiogenesis in a cancer prognosis and therapy
#66Methods for identifying compounds that modulate untranslated region-dependent gene expression and methods of using same
#67VEGF-Aassay
#68Use of VEGF-C agonists for inhibiting ultraviolet B-induced skin damage
#69Growth factor isoform
#70Method for assay on the effect of vascularization inhibitor
#71Composition comprising an angiopoietin-4 fragment
#72USE OF NUCLEOLIN AS A BIOMARKER FOR LYMPHANGIOGENESIS IN CANCER PROGNOSIS AND THERAPY
#73DIAGNOSTIC AND PROGNOSTIC ASSAY
#74Biomarker for colorectal cancer
#75BLOOD PROTEIN MARKERS IN METHODS AND APPARATUSES TO AID DIAGNOSIS AND MANAGEMENT OF SLEEP DISORDERED BREATHING
#76Treatment of Central Nervous System Disorders
#77NEUROPILIN-1 INHIBITORS
#78ENDOSTATIN AS A MARKER OF HEART FAILURE
#79Methods for Identifying Modulating Compounds of Lymphangiogenesis, Means Therefore, Compounds and Uses Thereof
#80Detection of Activation of Endothelial Cells as Surrogate Marker for Angiogenesis
#81TREATMENT OF POMPE DISEASE WITH SPECIFIC PHARMACOLOGICAL CHAPERONES AND MONITORING TREATMENT USING SURROGATE MARkERS
#82CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS
#83Three-dimensional microfluidic platforms and methods of use thereof
#84BIOMARKER FOR THE ESTIMATION OF ACUTE RENAL DISORDER AND PROGNOSIS OF THE DISORDER, AND USE OF THE BIOMARKER
#85Methods and compositions for the treatment and diagnosis of systemic anthrax infection
#86Methods and Compositions for the Diagnosis and Treatment of Angiogenic Disorders
#87Detection of risk of pre-eclampsia
#88Predicting renal failure in diabetes patients based on placental growth factor and soluble FLT-1
#89ANGIOPOIETIN-1 AND -2 BIOMARKERS FOR INFECTIOUS DISEASES THAT COMPROMISE ENDOTHELIAL INTEGRITY
#90STEM CELLS FOR USE IN LOCATING AND TARGETING TUMOR CELLS
#91Diagnostic assay for human matrix GLA-protein and its use as a biomarker
#92Growth factor isoform
#93Methods for determining the risk of prenatal complications
#94Methods of Modulating Angiogenesis
#95DETERMINING ATHEROSCLEROTIC LOAD USING PLACENTAL GROWTH FACTOR
#96Angiogenesis inhibitor
#97EG-VEGF nucleic acids and polypeptides and methods of use
#98Method of screening endothelial cells for angiogenic capability
#99METHODS AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF DISEASES CHARACTERIZED BY VASCULAR LEAK, HYPOTENSION, OR A PROCOAGULANT STATE
#100Carboline derivatives useful in the inhibition of angiogenesis
#101RAPID IN VIVO MODEL FOR ANGIOGENESIS
#102Method for assay on the effect of vascularization inhibitor
#103PLGF, FLT1 AND ENDOGLIN FOR DIAGNOSING ANGIOGENIC STATUS IN CORONARY ARTERY DISEASE
#104Dual variable domain immunoglobulins and uses thereof
#105HEPTbeta AS A TARGET IN TREATMENT OF ANGIOGENISIS MEDIATED DISORDERS
#106METHODS FOR BREAST CANCER SCREENING AND TREATMENT
#107Nogo-B receptor antagonists
#108Method for screening agent with angiogenic-modulating activities using teleost embryo
#109Determination of sFlt-1:angiogenic factor complex
#110Anti-angiogenic agents and methods of their use
#111Method of determining pregnancy toxemia
#112Binding partners of the placental growth factor, especially antibodies directed against the placental growth factor, and production and use thereof
#113Stationary Phase Antibody Arrays for Trace Protein Analysis
#114Methods for inhibiting angiogenesis with inhibitors of proadrenomedullin N-terminal 20 peptide (PAMP)
#115Platelet biomarkers for cancer
#116Vascular Tumor Markers
#117Methods for identifying anti-tumor and/or anti-angiogenesis drugs with deoxynucleoside 5′-monophosphate N-glycosidase as the target
#118TREATMENT PROTOCOL GENERATION FOR DISEASES RELATED TO ANGIOGENESIS
#119Novel Angiogenesis Inhibitor
#120Cytotrophoblast Stem Cell
#121Use of Angiopoietins in Tumor Therapy
#122Revascularization of Ischemic Retinal Tissue and Screening Method Therefor
#123Angiopoietin-like 2 as a biomarker of vascular endothelial cell abnormal function and senescence
#124CRBs as Modifiers of Branching Morphogenesis and Methods of Use
#125Methods and compositions for treating conditions involving abnormal angiogenesis
#126METHODS
#127Method of Screening Antiobesity Agents
#128Pharmaceutical compositions that modulate HPTPbeta activity
#129G proteins in tumor growth and angiogenesis
#130Method for decreasing blood glucose and improving glucose tolerance using angiopoietin-like protein 4
#131Methods of reducing skin damage and edema
#132Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
#133Methods of treating cancer, arthritis and/or diabetes with angiopoietins
#134Methods and compositions for inhibiting angiogenesis
#135EG-VEGF nucleic acids and polypeptides and methods of use
#136Methods for identifying compounds that modulate untranslated region-dependent gene expression and methods of using same
#137Tumor angiogenesis inhibitor alpha 1-antitrypsin
#138Modulation of angiogenesis through targeting of arginyl transferase (ATE1)
#139Methods for treating inflammatory disorders using regulators of microvessel dilations
#140Platelet biomarkers for the detection of disease
#141Detection of activation of endothelial cells as surrogate marker for angiogenesis
#142Modulation of endothelial cell surface receptor activity in the regulation of angiogenesis
#143Induction of the mitochondrial permeability transition
#144Compositions and methods for promoting angiogenesis
#145Stem cells for use in locating and targeting tumor cells
#146Detection and treatment of renal cancer
#147Platelet biomarkers for the detection of disease
#148Use of endosialin binding proteins to isolate endosialin positive cells
#149Neuropilin-1 inhibitors
#150Diagnosis of anemia and optimizing treatment for heart repair
#151Method of inhibiting angiogenesis
#152Multimarker panel based on PIGF for diabetes types 1 and 2
#153Antibodies to human vascular endothelial growth factor 2 and methods of using the same
#154Carboline derivatives useful in the treatment of cancer
#155KDR and VEGF/KDR binding peptides
#156Antibodies specific to KDR and uses thereof
#157Modulators of angiogenesis
#158Method of reducing angiogenesis
#159Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds
#160Method of screening endothelial cells for angiogenic capability
#161EG-VEGF nucleic acids and polypeptides and methods of use
#162VEGF isoforms and their use as anti-angiogenic, anti-vasodilatory, anti-permeability and anti-proliferative agents
#163Uses of vascular endothelial growth factor and type I collagen inducible protein (VCIP)